Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

17
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
17
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

473
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
473
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

633
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
633

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Corticosteroids on Pulmonary Function in a Large Cohort of Late Adolescents and Adults With Duchenne Muscular Dystrophy.

Muscle & nerve·2026
Same author

Guide to developing research recruitment strategies with the experts.

BMJ neurology open·2026
Same author

A qualitative study of enablers and barriers to healthy eating in adults with Charcot Marie Tooth disease using the Theoretical Domains Framework and COM-B model.

Journal of health psychology·2026
Same author

Fatigue as a modifier of diet quality in adults with Charcot Marie Tooth disease.

Journal of neuromuscular diseases·2025
Same author

Exploring psychosocial experiences in clinically stable generalised Myasthenia Gravis: A thematic analysis.

Journal of neuromuscular diseases·2025
Same author

Updated demographics categories to capture the true diversity of an international registry of rare disease patients.

Therapeutic advances in rare disease·2025

Related Experiment Video

Updated: Apr 20, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.7K

Ongoing developments in sporadic inclusion body myositis.

Pedro M Machado1, Mhoriam Ahmed, Stefen Brady

  • 1MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, Box 102, 8-11 Queen Square, London, WC1N 3BG, UK, p.machado@ucl.ac.uk.

Current Rheumatology Reports
|November 18, 2014
PubMed
Summary

Sporadic inclusion body myositis (IBM) is an acquired muscle disease with no cure. Research is advancing diagnostic tools and exploring novel therapies, but its cause remains unclear.

More Related Videos

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.7K
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

1.1K
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
06:52

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases

Published on: September 29, 2014

54.8K

Area of Science:

  • Neurology
  • Immunology
  • Muscle Biology

Background:

  • Sporadic inclusion body myositis (IBM) is an acquired, age-related muscle disorder.
  • Currently, no effective treatments exist for IBM.
  • The exact cause (aetiopathogenesis) of IBM is still uncertain.

Purpose of the Study:

  • To review ongoing developments in understanding and managing sporadic inclusion body myositis (IBM).
  • To highlight advancements in diagnostics, pathogenesis insights, and therapeutic strategies for IBM.
  • To emphasize the need for a collaborative approach to improve IBM patient care.

Main Methods:

  • Review of recent genetic studies and autoantibody discoveries in IBM.
  • Analysis of histopathological markers and clinical diagnostic utility.
  • Evaluation of MRI's role and emerging therapeutic trials (e.g., protein homeostasis, myostatin blockers).

Main Results:

  • Significant progress in identifying potential diagnostic markers and understanding IBM pathogenesis.
  • Novel therapeutic strategies are under investigation, targeting underlying disease mechanisms.
  • The role of exercise in IBM management is an active area of research.

Conclusions:

  • Despite advancements, the aetiopathogenesis of sporadic inclusion body myositis remains elusive.
  • Multidisciplinary collaboration is essential for improving diagnosis, treatment, and patient care in IBM.
  • Continued research into genetic factors, biomarkers, and targeted therapies is crucial for effective IBM management.